Organization Profile

You just read:

New study involving 10 canadian research sites shows high cure rates for genotype 1 hepatitis C using new Bristol-Myers Squibb all-oral daclatasvir TRIO fixed-dose combination

News provided by

Bristol-Myers Squibb Canada

Nov 13, 2014, 05:59 ET